Overview
- AbbVie will offer selected medicines at Most-Favored-Nation or discounted prices for Medicaid and through the TrumpRx cash-purchase portal.
- Products cited by the company include Humira, Alphagan, Combigan and Synthroid, with specific discount levels not disclosed.
- The company committed $100 billion over the next decade to U.S. research, development and capital investments, including manufacturing.
- In exchange, the White House granted AbbVie a three-year exemption from tariffs and future pricing mandates.
- The pact is one of more than a dozen similar deals under the administration’s MFN initiative, while analysts say the limited scope and confidentiality make the overall consumer and Medicaid impact hard to gauge.